These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27037127)

  • 1. Immunoaffinity extraction using conformation-dependent antibodies coupled to SE-HPLC for the development of stability and potency-indicating assay for quadrivalent human papillomavirus vaccine.
    Mostafa MM; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():211-217. PubMed ID: 27037127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization and validation of ELISA immunoassay for the evaluation of in-vitro relative potency of a four-component human papillomavirus vaccine products.
    Mostafa MM; Al-Ghobashy MA; Fathalla FA; Salem MY
    Biologicals; 2016 Nov; 44(6):596-599. PubMed ID: 27522938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography.
    Ladd Effio C; Oelmeier SA; Hubbuch J
    Vaccine; 2016 Mar; 34(10):1259-67. PubMed ID: 26845741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens.
    Yang Y; Li H; Li Z; Zhang Y; Zhang S; Chen Y; Yu M; Ma G; Su Z
    Vaccine; 2015 Feb; 33(9):1143-50. PubMed ID: 25604799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Quantitative analysis of nine types of virus-like particles in human papilloma virus bulk by size-exclusion chromatography].
    Long Z; Li X; Li X; Liu J; Nie J; Li C; Li Y; Huang T; Huang W
    Se Pu; 2021 Apr; 39(4):424-429. PubMed ID: 34227763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production and purification of human papillomavirus type 33 L1 virus-like particles from Spodoptera frugiperda 9 cells using two-step column chromatography.
    Baek JO; Seo JW; Kim IH; Kim CH
    Protein Expr Purif; 2011 Feb; 75(2):211-7. PubMed ID: 20716445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between Dynamic Light Scattering and Size Exclusion High Performance Liquid Chromatography for Monitoring the Effect of pH on Stability of Biopharmaceuticals.
    Al-Ghobashy MA; Mostafa MM; Abed HS; Fathalla FA; Salem MY
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():1-9. PubMed ID: 28578190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties.
    Zhao Q; Li S; Yu H; Xia N; Modis Y
    Trends Biotechnol; 2013 Nov; 31(11):654-63. PubMed ID: 24125746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
    Jerajani K; Wan Y; Hickey JM; Kumru OS; Sharma N; Pullagurla SR; Ogun O; Mapari S; Whitaker N; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2022 Nov; 111(11):2983-2997. PubMed ID: 35914546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
    Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
    Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next generation polyphosphazene immunoadjuvant: Synthesis, self-assembly and in vivo potency with human papillomavirus VLPs-based vaccine.
    Marin A; Chowdhury A; Valencia SM; Zacharia A; Kirnbauer R; Roden RBS; Pinto LA; Shoemaker RH; Marshall JD; Andrianov AK
    Nanomedicine; 2021 Apr; 33():102359. PubMed ID: 33476764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples.
    Shank-Retzlaff M; Wang F; Morley T; Anderson C; Hamm M; Brown M; Rowland K; Pancari G; Zorman J; Lowe R; Schultz L; Teyral J; Capen R; Oswald CB; Wang Y; Washabaugh M; Jansen K; Sitrin R
    Hum Vaccin; 2005; 1(5):191-7. PubMed ID: 17012876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli.
    Lagoutte P; Mignon C; Donnat S; Stadthagen G; Mast J; Sodoyer R; Lugari A; Werle B
    J Virol Methods; 2016 Jun; 232():8-11. PubMed ID: 26947397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.
    Jerajani K; Wan Y; Kumru OS; Pullagurla SR; Kumar P; Sharma N; Ogun O; Mapari S; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
    J Pharm Sci; 2023 Feb; 112(2):446-457. PubMed ID: 36096284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
    Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
    J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV vaccine cross-protection: Highlights on additional clinical benefit.
    De Vincenzo R; Ricci C; Conte C; Scambia G
    Gynecol Oncol; 2013 Sep; 130(3):642-51. PubMed ID: 23747835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions.
    Chen J; Ni G; Liu XS
    Cell Immunol; 2011; 269(1):5-9. PubMed ID: 21477796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.